Neglected diseases and drugs to counter addiction represent unmet medical needs, but they have been areas that pharmaceutical companies have been reluctant to pursue. Savant HWP is in clinical development on an experimental drug that targets both of these indications. We spoke to Stephen Hurst, CEO of Savant HWP about the company’s strategy, the unique compound that can address two seemingly unrealated indications, and the role priority review vouchers can play in providing drug developers with incentives to pursue indications that might otherwise be ignored.